REAL TIME Cancer Conference Coverage: A Novel Methodology for Authentic Reporting on Presentations and Discussions launched via Twitter.com @ The 2nd ANNUAL Sachs Cancer Bio Partnering & Investment Forum in Drug Development, 19th March 2014 • New York Academy of Sciences • USA
Author, Curator, Life Sciences Reporter: Aviva Lev-Ari, PhD, RN
Article ID #123: REAL TIME Cancer Conference Coverage: A Novel Methodology for Authentic Reporting on Presentations and Discussions launched via Twitter.com @ The 2nd ANNUAL Sachs Cancer Bio Partnering & Investment Forum in Drug Development, 19th March 2014 • New York Academy of Sciences • USA. Published on 3/21/2014
WordCloud Image Produced by Adam Tubman
This article is by the same Curator as the following published on 1/4/2014:
conceived: NEW Definition for Co-Curation in Medical Research
RELATED ARTICLES
Cancer Biology and Genomics for Disease Diagnosis, Volume One Pre-ePub Announcement
Volatile Organic Compounds (VOCs) as Biomarkers in Cancer Detection: • Alnion Ranked #1 in “Top 10 Israeli medical advances to watch in 2014”.
Investing and inventing: Is the Tango of Mars and Venus Still on
Curator’s Position Statement
The complexity of presentations in Scientific Conferences requires a different Reporting methodology than the idea summarization by Science Journalists.
A Novel Methodology was applied @ The 2nd ANNUAL Sachs Cancer Bio Partnering & Investment Forum Promoting Public & Private Sector Collaboration & Investment in Drug Development, 19th March 2014 • New York Academy of Sciences • USA
Launched a novel methodology for Authentic Reporting on Presentations and Discussions in my quest to achieve REAL TIME Cancer Conference Coverage of content and Q&A.
Of all Social Media modalities I used the following:
- Primary: Tweeting key idea by EVERY SPEAKER
- Secondary: Tweeting all Q&A and Discussions
- FaceBook posting
- LinkedIn posting
- WordPress.com e-Publishing @ http://pharmaceuticalinteligence.com
Below I present ALL the Tweets and the Retweets for 3/19/2014
Public and Private Partnership @ The 2nd ANNUAL Sachs Cancer Bio Partnering & Investment Forum Promoting Public & Private Sector Collaboration & Investment in Drug Development, 19th March 2014 • New York Academy of Sciences • USA
March 19, 2014 by 2012pharmaceutical
- Louis J. DeGennaro, Interim President and CEO, Chief Mission O cer, The Leukemia and Lymphoma Society
- Beth Jacobs, Managing Partner, Excellentia Global Partners Featuring:
- Darryl Mitteldorf, Executive Director, Global Prostate Cancer Alliance
- Dov Hass, Associate, Morgan, Lewis & Bockius LLP
- Kristina Khodova, Head of Oncology Projects, Biomed Cluster, Skolkovo Foundation
- Louise M. Perkins, Chief Science O cer, Melanoma Research Alliance
- Peter L. Hoang, Managing Director, O ce of Innovations, Technology Based Ventures, The University of Texas MD Anderson Cancer Center
- Steven Young, President & COO, Addario Lung Cancer Medical Institute
- Walter M. Capone, President, Multiple Myeloma Research Foundation
- Foundation are playing a new role: The enable Cancer Research, links to biopharma, Scientific staff, understanding of the commercial landscape
- Universities: Public & Private
Question #1: Difficulties in working with small biotech companies Non-Profits are disease focus, Biotech have expectation to gain capital funding from the Non-Profits Non-Profit has access to Patients information and disease condition in the pre-approval period, Consortia: addresses access to Resources do not invest or fund pharma companies, they fund diagnostics lab, stem cell companies Foundations have right to publish data, IP ownership is still unresolved an issue, Dana Farber can’t be encouraged to give away its IP but a Foundation can accelerate the process.
IP Licensing Academic institution as LICENSORS WHILE HAVING having bond obligation, Tax exempt status is exclusive, while the bond owner status is non-exclusive Appetite for Risk – Venture Capital vs Foundation
- Louis J. DeGennaro, Interim President and CEO, Chief Mission O cer, The Leukemia and Lymphoma Society – provides $60 millions a year for R&D – they do take significant Risk. Size of population of patients is not a factor, serving all is. No detection, No screening, Patients present with full blown disease
- Darryl Mitteldorf, Executive Director, Global Prostate Cancer Alliance — Risk does not belong to this organization. Foundation funded research on the disparity between Black and White patients.
- Louise M. Perkins, Chief Science O fficer, Melanoma Research Alliance – UV cause, funding research for personalized. medicine. Foundation has educated FDA, Sequencing of melanoma larger that sequencing of the Genome
- Steven Young, President & COO, Addario Lung Cancer Medical Institute 70% of Lung Cancer Patients were not Smokers
__________________
8:00 AM –
On the 40th Floor of 7 World Trade Center in NYC @ The 2nd ANNUAL Sachs Cancer Bio Partnering & Investment Forum Promoting Public & Private Sector Collaboration & Investment in Drug Development, 19th March 2014 • New York Academy of Sciences • USA
Follow me @pharma_BI and @AVIVA1950
- Event Coverage
- Cancer & Genomic – Volume One in LPBI’s BioMed e-Series C: Cancer
- Alnion Venture Funding Prospecting & Negotiation
Aviva Lev-Ari, PhD, RN Founder and Director Leaders in Pharmaceutical Business Intelligence
Editor-in-Chief http://pharmaceuticalintelligence.com
TWEET LOG for 3/19/2014
-
TODAY follow my Tweets
@pharma_BI coverage for The 2nd ANNUAL Sachs Cancer Bio Partnering &… http://fb.me/1dvGXjXQC -
Checkpoint inhibitors: Portfolio of antigens for a small # Tumors. Adjuvant combinations Risks: immune disease vs Cancer
-
Argos Therapeutics: Leader in immunotherapy for Advanced Kidney cancer, vaccine development effort
-
Tumor blockade via immunotherapy: active therapy, autologos, T cells depleted by kidney and tumor removal, healthy kidney was protected
-
Precursors of breast lesions, target antigen, vaccine for cancer MAY or not evolve into immune event in the future
-
Immunotherapy in Cancer: Tolerance of Cancer, central (thymus) breast/ovarian vs peripheral by checkpoint: skin, lungs, kidney vs
-
Florian Schodel, Philimmune, immunotherapy in Cancer Development: vaccine for Cancer for secondary prevention breast/ovarian cancer
-
All Options on the table when financing, best package requires flexibility. Outcome, Output, Process originality do clinical trial, find what kills
-
Partnering in Phase I is dangerous vs Stage IV, companion diagnostics, not enough money in the product to share.
-
Future Trends in Oncology: preclinical going IPO, China for clinical trial at different standard of care than US or Europe
-
Carole Nuechterlein, Head Roche Venture Fund: Big Pharma offers to biotech knowledge on combination drugs to select for development. Biotech tend to overestimate value of the assets
-
Tim Herpin, Head Transactions (UK) BD AstraZeneca: Acquisition is preferred to partnership
-
Stuart Barich, Oppenheimer & Co. Holding to assets vs. Partnering – HOLD as long as a biotech can
-
Anne Altmeyer, VP Oncology, Novartis: Only 5% of all Cancer drugs move from Phase I to phase II – Oncology drugs 36% of all current cancer drugs are in Phase II
-
Commercialization is only one factor in Transforming Patient life’s by drug response in clinical trials – repurposed drugs vs generic
-
Regulatory affairs: 30% of applications are approved, most cancer indications requires orphan drug development – niche of patient
-
Celgene partners with Foundation Medicine or Diagnostics development, Roche has own Diagnostics – small biotech vs big Pharma
-
Guillaume Vignon, Dir BD, EMD Serono: Finding the right patient by selection for obtaining response – key for clinical study success & Translational Team
-
Anne Altmeyer, VP Oncology Novartis: Strategies for Small Molecule and Biologicals Drug Development, 1/3 of top 100 drugs and 22% of drug approval are Biologicals this is the future
-
Moffitt Total Cancer Care DB Solid Tumor signature – Cancer Vaccine, genotype—>>>>phenotype demographic histology over expression of genes
-
M2GEN – Concortium with Community Hospitals: WORLD largest biorepository Moffitt/Merck/Community Hospital, Genomic Marker
-
J. Mule, Moffitt Cancer Center: Translational Research for Personalized Medicine: M2GEN collaboration StateMerck/Moffitt 3rd largest in US
-
BRAF inhibition: not enough patients for genetic mutation based clinical trial, BiomarkersDiagnostics in collaboration w/academia is optimal
-
TODAY follow my Tweets
@pharma_BI coverage for The 2nd ANNUAL Sachs Cancer Bio Partnering &… http://fb.me/1jxkUHMlJ -
N.C. Dracopoli of Janssen R&D: Biomarkers for Diagnosis – Prognosis, Predicative test, pharmacodygnostic test FDA 32 genomics biomarkers approved
-
Tx w/anti-IL-6 for ALL – Great Prognosis, Novartis and UPenn collaboration most promising big Pharma and Academia case
-
Philip Gotwals, Oncology Novartis, Translational Research, collaboration with UPenn – Org clarity challenging
-
TODAY follow my Tweets
@pharma_BI coverage for The 2nd ANNUAL Sachs Cancer Bio Partnering & Investment Forum Promoti…http://lnkd.in/dbHd85U -
TODAY follow my Tweets
@pharma_BI coverage for The 2nd ANNUAL Sachs Cancer Bio Partnering & Investment Forum… http://wp.me/p2kEDv-5AX -
Cancer Biology and Genomics for Disease Diagnosis, Volume One Pre-ePub Announcement http://lnkd.in/d83gUrY
-
Power of Analogy: Curation in Music, Music Critique as a Curation and Curation of Medical Research Findings – A Comp…http://lnkd.in/dBbahTf
Aviva Lev-Ari @AVIVA1950 Mar 19
@pharma_BI -
TODAY follow my Tweets
@pharma_BI coverage for The 2nd ANNUAL Sachs Cancer Bio Partnering & Invest… http://wp.me/p2kEDv-5AX via@Pharma_BI -
Small molecule peptides Roche, Amgen players RNA
-
Providus Therapeutics – preclinical small molecule targeting selective kinase inhibitors, mutations, Solution overcoming compensatory feedback
-
TBI 302 Liver Cancer TBI 304 Stimulated hemoglobin – Cancer thirty causes anemia SAME market as EPO
-
Therapure Biopharma: Liver cancer, purify hemoglobine, protein drug carrier for drug payload
-
Avastin approved for recurring Gliomas
-
Neonc Technologies INTERNASAL Brain delivery using CPAP via cranial nerse, by pass BBB. Malignant Gliomas 12-15 mo survival
-
Sapherion Therapeutics since 2002 – Myocet: Anthracycline – doxorubicin in combination with transtuzumab and pactistaxal Phase III trial
-
Rexahn Pharmaceuticals phase II – Cancer cell specific nucleotide compound that inhibit DNA Synthesis in animal models,
-
Children Oncology Local & Metastatic – 2000 kids in US receive Platinum drugs in US. Payers receptive to pay Platinum drug. STS since 2003
-
Adherex Technologies, Inc. RTP, NC seeking Partners for Phase III, Platinum drugs, causes hearing loss in children, Adults neck CA
-
Rgenix Inc. 100% reduction in Liver methastasis, from colon cancer, relapse in 2-3 years, require work is collaboration with Rockfeller University
-
Rgenix, Inc. drug for tumor suppression by gene Apolipho E* 50% survival data fro Sloan Kettering, 80% tumor growth inhibition
-
Significant extension of life: Pre clinical research results by Intensity Therapeutics
-
Intensity Therapeutics: Drug diffuse to cell increasing fusion, tumor regression vs inhibition of growth: completed systemic response 40 days
Re-TWEETS
1. @pharma_BI @Pharma_BI Mar 19
Future Trends in Oncology: preclinical gong IPO, China for clinical trial at different standard of care than US or Europe
- Retweet 1: Gil Press
- Favorite 1: Kimberly Ha
- 8:23 AM – 19 Mar 2014 · Details
2. @pharma_BI @Pharma_BI Mar 19
Big Pharma offers to biotech knowledge on combination drugs to select for development. Biotech tend to overestimate value of the assets
- Retweet 1: Gil Press
8:35 AM – 19 Mar 2014 · Details
3. @pharma_BI @Pharma_BI Mar 19
Only 5% of all Cancer drugs move from Phase I to phase II -Oncology drugs 36% of all current cancer drugs are in Phase II
7:51 AM – 19 Mar 2014 · Details
4. @pharma_BI @Pharma_BI Mar 19
Commercial only one factor in Transforming Patient life’s by drug response in clinical trials – repurposed drugs vs generic
- Retweet 1 – Gil Press
5. @pharma_BI @Pharma_BI Mar 19
Celgene partners with Foundation Medicine or Diagnostics development, Roche has own Diagnostics – small biotech vs big Pharma
- Retweet 1 – Gil Press
7:03 AM – 19 Mar 2014 · Details
6. @pharma_BI @Pharma_BI Mar 19
TODAY follow my Tweets @pharma_BI coverage for The 2nd ANNUAL Sachs Cancer Bio Partnering &… http://fb.me/1jxkUHMlJ
- Retweet 1 – Gil Press
6:16 AM – 19 Mar 2014 · Details
7. @pharma_BI @Pharma_BI Mar 14
The 2nd ANNUAL Sachs Cancer Bio Partnering & Investment Forum Promoting Public & Private Sector Col… http://wp.me/p2kEDv-55i via @Pharma_BI
Retweeted by @pharma_BI
8. Sachs Associates Ltd @SachsAssociates Dec 10
2nd Annual SachsCancerBioPartnering Forum, 19th March, New York. Info: http://goo.gl/GLD3Dg Early Bird Registration:http://goo.gl/rX0RpW
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aptubman
Arav Gandhi
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
zraviv06
zs22
Leave a Reply